Lipid model membranes for drug interaction study

European Biophysics Journal

Volumn 35, Issue 5, 2006, Pages 431-438

  Cavalcanti, L P ^a   Konovalov, O ^a   Torriani, I L ^b  

^a EUROPEAN SYNCHROTRON RADIATION FACILITY   (France)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Diffraction; Langmuir films; Lipid model membranes

Indexed keywords

AMPHOLYTE; ANTINEOPLASTIC AGENT; DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DIPALMITOYLPHOSPHATIDYLSERINE; ELLIPTICINE; GLYCEROPHOSPHOLIPID; HYDROCARBON; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG INTERACTION; DRUG STRUCTURE; DRUG TARGETING; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; LIPID MEMBRANE; MATHEMATICAL ANALYSIS; SOLID; STRUCTURE ANALYSIS; TUMOR CELL; X RAY DIFFRACTION;

COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; ELLIPTICINES; LIPID BILAYERS; MEMBRANE FLUIDITY; MODELS, CHEMICAL; MODELS, MOLECULAR; PHOSPHOLIPIDS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33646465840     PISSN: 01757571     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00249-006-0050-1     Document Type: Article

References (15)

1. Bangham AD (1968) Membrane models with phospholipids. Prog Biophys Mol Biol 18:29-36
2. Cavalcanti LP et al (2005) Drug loading to lipid-based cationic nanoparticles. Nucl Instr Meth B 238:290-293
3. Courseille C et al (1974) Structure Cristalline et Moléculaire du Diméthyl-5,11 6H-Pyrido[4,3-b]carbazole (Ellipticine). Acta Cryst B30:2628-2631
4. El Mashak EM et al (1979) Interactions between ellipticine and some derivatives and phospholipids in model membranes. FEBS Lett 107:155-159
5. Fradin C (1999) These de doctorat, Universite Paris-6, France
6. Kaganer VM, Loginov EB (1995) Symmetry and phase-transitions in langmuir monolayers - the Landau theory. Phys Rev E 51:2237-2249
7. Kaganer VM et al (1995) Tilted phases of fatty acid monolayers. J Chem Phys 102:9412-9422
8. Kaganer VM et al (1999) Structure and phase transitions in Langmuir monolayers. Rev Mod Phys 71:779-819
9. Kohn K et al (1975) Intercalative binding of ellipticine to DNA. Cancer Res 35:71-76
10. Konovalov O et al (2002) Lipid discrimination in phospholipid monolayers by the antimicrobial frog skin peptide PGLa. A synchrotron X-ray grazing incidence and reflectivity study. Eur Biophys J 31: 428-437
11. Mathe G et al (1998) Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation'. Biomed Pharmacother 52:391-396
12. Sainsbury M (1990) Ellipticines. In: Wilman D (ed) The chemistry of antitumor agents. Chapman and Hall, New York, pp 410-435
13. Singh MP et al (1994) High-field NMR and restrained molecular modeling studies on a DNA heteroduplex containing a modified apurinic abasic site in the form of covalently linked 9-aminoellipticinet. Biochemistry 33:10271-10285
14. Sirota EB et al (1993) Rotator phases of the normal alkanes: an X-ray scattering study. J Chem Phys 98:5809-5824
15. Stiborová M et al (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmac 62:1675-1684